Biopharmaceutical company: Global Blood Therapeutics (GBT)

Global Blood Therapeutics, Inc. (NASDAQ: GBT), founded in February 2011, headquartered in South San Francisco, California, USA, with 457 full-time employees, is a clinical Biopharmaceutical Company , focusing on the discovery, development and commercial application of innovative therapies for serious blood diseases.

The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks- https://www.mg21.com/gbt.html

Global Blood Therapeutics (GBT)

Global Blood Therapeutics is developing its main product candidate drug voxelotor (GBT440), an oral, once daily treatment for sickle cell disease (SCD). SCD is characterized by severe pain, multiple organ damage and high early mortality. The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks- https://www.mg21.com/gbt.html

Global Blood Therapeutics is conducting a phase III clinical trial of voxelotor in adult and adolescent SCD patients. The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks- https://www.mg21.com/gbt.html

Global Blood Therapeutics also evaluated the safety and pharmacokinetics of single and multiple doses of body fluids in phase IIa clinical trials in adolescents and pediatric SCD patients. The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks- https://www.mg21.com/gbt.html

Voxelotor can target sickle red blood cells for treatment, and has the potential to treat SCD and its related symptoms. In addition to voxelotor, Global Blood Therapeutics is using its profound scientific expertise to develop a series of chemical and biological agents for the treatment of blood diseases, including hypoxic pulmonary diseases and hereditary vascular edema (embolism). The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks- https://www.mg21.com/gbt.html

The company's related products have applied for patent protection in Europe, the United States and other major markets. The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks- https://www.mg21.com/gbt.html

In May 2022, according to Wedbush analysts Pfizer (PFE) Acquired with about US $11.6 billion Biohaven Pharmaceutical Later, Global Blood Therapeutics (NASDAQ: GBT) may become a potential acquisition target in the field of biotechnology. The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks- https://www.mg21.com/gbt.html

On August 5, 2022, the Wall Street Journal reported that, Pfizer (PFE) is negotiating to acquire at a price of about USD 5B Global blood therapy (NASDAQ stock code: GBT). The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks- https://www.mg21.com/gbt.html

On September 30, 2002, Global Blood Therapeutics (NASDAQ: GBT) said in a regulatory document that it would complete the cooperation with Pfizer (NYSE: PFE). The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks- https://www.mg21.com/gbt.html

Global Blood Therapeutics (GBT) US equity investment

GBT submitted on July 9, 2015 IPO The prospectus was launched on NASDAQ on August 12/2015 with an IPO price of US $20, 6 million shares issued and US $120 million raised for product research. The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks- https://www.mg21.com/gbt.html

In August 2022, Pfizer (PFE) and Johnson&Johnson (JNJ) bid for Global Blood Therapeutics (NASDAQ stock code: GBT), and Pfizer won with an offer of $5.4 billion. In October 2022, Pfizer completed the acquisition of GBT Delisting 。